| Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials … A Du Bois, A Reuss, E PujadeLauraine, P Harter, I RayCoquard, ... Cancer 115 (6), 1234-1244, 2009 | 1809 | 2009 |
| Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial E Pujade-Lauraine, F Hilpert, B Weber, A Reuss, A Poveda, G Kristensen, ... Journal of clinical oncology 32 (13), 1302-1308, 2014 | 1697 | 2014 |
| Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised … E Pujade-Lauraine, JA Ledermann, F Selle, V Gebski, RT Penson, ... The lancet oncology 18 (9), 1274-1284, 2017 | 1688 | 2017 |
| Olaparib plus bevacizumab as first-line maintenance in ovarian cancer I Ray-Coquard, P Pautier, S Pignata, D Pérol, A González-Martín, ... New England Journal of Medicine 381 (25), 2416-2428, 2019 | 1573 | 2019 |
| Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial EM Swisher, KK Lin, AM Oza, CL Scott, H Giordano, J Sun, GE Konecny, ... The lancet oncology 18 (1), 75-87, 2017 | 1165 | 2017 |
| ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease N Colombo, C Sessa, A du Bois, J Ledermann, WG McCluggage, ... Annals of oncology 30 (5), 672-705, 2019 | 1084 | 2019 |
| Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO JY Blay, S Bonvalot, P Casali, H Choi, M Debiec-Richter, AP Dei Tos, ... Annals of Oncology 16 (4), 566-578, 2005 | 1011 | 2005 |
| Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic … T Bachelot, C Bourgier, C Cropet, I Ray-Coquard, JM Ferrero, G Freyer, ... Journal of Clinical Oncology 30 (22), 2718-2724, 2012 | 880 | 2012 |
| Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome M Gobert, I Treilleux, N Bendriss-Vermare, T Bachelot, S Goddard-Leon, ... Cancer research 69 (5), 2000-2009, 2009 | 869 | 2009 |
| Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas I Ray-Coquard, C Cropet, M Van Glabbeke, C Sebban, A Le Cesne, ... Cancer research 69 (13), 5383-5391, 2009 | 794 | 2009 |
| Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for … S Sleijfer, I Ray-Coquard, Z Papai, A Le Cesne, M Scurr, P Schöffski, ... Journal of clinical oncology 27 (19), 3126-3132, 2009 | 771 | 2009 |
| Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials J Bohlius, K Schmidlin, C Brillant, G Schwarzer, S Trelle, J Seidenfeld, ... The Lancet 373 (9674), 1532-1542, 2009 | 725 | 2009 |
| Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study N Penel, BN Bui, JO Bay, D Cupissol, I Ray-Coquard, ... Journal of Clinical Oncology 26 (32), 5269-5274, 2008 | 701 | 2008 |
| Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing F Ducimetière, A Lurkin, D Ranchère-Vince, AV Decouvelaere, M Péoc'h, ... PloS one 6 (8), e20294, 2011 | 613 | 2011 |
| Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism … I Ray-Coquard, JY Blay, A Italiano, A Le Cesne, N Penel, J Zhi, F Heil, ... The lancet oncology 13 (11), 1133-1140, 2012 | 604 | 2012 |
| Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up ESMO/European Sarcoma Network Working Group Annals of oncology: official journal of the European Society for Medical …, 2014 | 537 | 2014 |
| Dendritic cell infiltration and prognosis of early stage breast cancer I Treilleux, JY Blay, N Bendriss-Vermare, I Ray-Coquard, T Bachelot, ... Clinical Cancer Research 10 (22), 7466-7474, 2004 | 521 | 2004 |
| Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial A Le Cesne, JY Blay, I Judson, A Van Oosterom, J Verweij, J Radford, ... Journal of Clinical Oncology 23 (3), 576-584, 2005 | 517 | 2005 |
| Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of … JY Blay, A Le Cesne, I Ray-Coquard, B Bui, F Duffaud, C Delbaldo, ... Journal of clinical oncology 25 (9), 1107-1113, 2007 | 507 | 2007 |
| Lenvatinib plus pembrolizumab for advanced endometrial cancer V Makker, N Colombo, A Casado Herráez, AD Santin, E Colomba, ... New England Journal of Medicine 386 (5), 437-448, 2022 | 506 | 2022 |
